All In Biotech

Drug Trial Radar · NCT00664846

Standard Medical Management in Secondary Prevention of Ischemic Stroke in China

Standard Medical Management in Secondary Prevention of Ischemic Stroke in China.

Last checked: Nov 19, 2026Latest source record: Apr 11, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 4,000 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,000

Planned (sponsor's estimate)

Start

Apr 2008

Primary completion

Dec 2010

Study completion Apr 2011

Sponsor

Lead sponsor
Peking Union Medical College HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 23, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purposes of the study are to analyse the cross-section data of secondary stroke prevention in China and to carry out a standard medical management including medicine and interactive education program,and to evaluate the efficacy and safety of the standard medical management in secondary stroke prevention.

Conditions

  • Stroke

Interventions

  • Aspirin / Clopidogrel, Atorvastatin / SimvastatinDrug

    Standard Medical Management,including antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide) .

  • Asprin / Clopidogrel, Atorvastatin / SimvastatinDrug

    Antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Success Rate of standard medical managementTime frame: 1 year after enrolled

Locations

46 sites in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hosptial

    Beijing, Beijing Municipality, China

  • China Pla General Hospital

    Beijing, Beijing Municipality, China

  • Beijing Daxing District Hospital

    Beijing, Beijing Municipality, China

  • Beijing Ji Shui Tan Hospital,the 4Th Medical College of Peking University

    Beijing, Beijing Municipality, China

  • Beijing Shijitan Hospital

    Beijing, Beijing Municipality, China

  • Beijing Tiantan Hospital

    Beijing, Beijing Municipality, China

  • China Rehabilition Research Center

    Beijing, Beijing Municipality, China

  • General Hospital of Navy

    Beijing, Beijing Municipality, China

  • Luhe Hospital of Tongzhou Distict Beijing

    Beijing, Beijing Municipality, China

  • No 263 Hospital of Pla

    Beijing, Beijing Municipality, China

  • No 309 Hospital of Pla

    Beijing, Beijing Municipality, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

  • Pinggu County Hospital Beijing

    Beijing, Beijing Municipality, China

  • Xuanwu Hospital Capital Medical University

    Beijing, Beijing Municipality, China

  • Daping Hospital

    Chongqing, Chongqing Municipality, China

  • Southwest Hospital

    Chongqing, Chongqing Municipality, China

  • Guangzhou First Municipal People'S Hospital

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital,Sun Yat-Sen Unversity

    Guangzhou, Guangdong, China

  • The First Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • The Second Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • The Third Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • Yutian County Hospital

    Yutian, Hebei, China

  • Hebei North University

    Zhangjiakou, Hebei, China

  • The First Hospital of Harbin Medical University

    Harbin, Helongjiang, China

  • The Second Hospital of Harbin Medical University

    Harbin, Helongjiang, China

  • Henan Provincial People'S Hospital

    Zhengzhou, Henan, China

  • The Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China

  • Xiangya Hospital of Centre-South University

    Changsha, Hunan, China

  • Inner Mongolia Baotou City Central Hospital

    Baotou, Inner Mongolia, China

  • The Appurtenant Hospital of Chifeng University

    Chifeng, Inner Mongolia, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China

  • Nanjing General Hospital of Nanjing Military Command

    Nanjing, Jiangsu, China

  • The Affiliated Drumtower Hospital of Nanjing University Medical School

    Nanjing, Jiangsu, China

  • Jilin University

    Changchun, Jilin, China

  • The Third People'S Hospital of Dalian

    Dalian, Liaoning, China

  • The First Affiliated Hospital of China Medical Sciences University

    Shenyang, Liaoning, China

  • Qinghai Provincial People'S Hospital

    Xining, Qinghai, China

  • Qilu Hospital of Shangdong University

    Jinan, Shandong, China

  • The Second Hospitalof Shangdong University

    Jinan, Shandong, China

  • Huashan Hospital Fudan University

    Shanghai, Shanghai Municipality, China

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.